Roche says divarasib cut risk of death 44% in lung cancer trial

ZURICH, Oct 25 (Reuters) – Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced the risk of death by 44% compared with existing treatments in a phase III study. •

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)